Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. 詳細を表示
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing...
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.34 | -9.88372093023 | 3.44 | 3.47 | 2.8205 | 30541 | 3.02730556 | CS |
4 | -0.9 | -22.5 | 4 | 4.49 | 2.8205 | 26054 | 3.64533518 | CS |
12 | -0.38 | -10.9195402299 | 3.48 | 5.02 | 2.4377 | 36937 | 3.37915807 | CS |
26 | -0.58 | -15.7608695652 | 3.68 | 5.99 | 2.4377 | 30654 | 3.8191676 | CS |
52 | 0.49 | 18.7739463602 | 2.61 | 6.1568 | 2.4377 | 40005 | 4.26920191 | CS |
156 | -10 | -76.3358778626 | 13.1 | 13.34 | 0.6706 | 402046 | 4.62358924 | CS |
260 | -25.5 | -89.1608391608 | 28.6 | 37.7 | 0.6706 | 608254 | 16.05837636 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約